CPT1A and acute myeloid leukemia: Restricting K-M OS survival analyses to AML patients with distinct mutations revealed that upregulated levels of NDUFA6, SDHA and CPT1A were associated with unfavourable prognosis in mutated IDH1 AML patients (Table 3).